Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 5/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344059 | 0.91 | TSHR (0.61) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL8621469 | 0.89 | TSHR (0.70) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL26189830 | 0.87 | TSHR (0.67) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL1001167 | 0.85 | TSHR (0.58) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL2640223 | 0.84 | TSHR (0.70) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL19520 | 0.84 | TSHR (0.70) | TSHRIDO1AGXTALDH1A1 | |
| SCHEMBL3488296 | 0.83 | TSHR (0.56) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL8998380 | 0.83 | TSHR (0.56) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL9011595 | 0.82 | TSHR (0.67) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL9011624 | 0.82 | TSHR (0.67) | TSHRTDP1L3MBTL1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| EP-4214189-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL Business Ltd (GB) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022058733-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS PLC (GB) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | TTR, C1R, APOB | TSHR 218/4885TDP1 3163/4885L3MBTL1 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.